Literature DB >> 25053248

Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients.

Jan J De Waele1, J Lipman, M Akova, M Bassetti, G Dimopoulos, M Kaukonen, D Koulenti, C Martin, P Montravers, J Rello, A Rhodes, A A Udy, T Starr, S C Wallis, J A Roberts.   

Abstract

PURPOSE: Risk factors for β-lactam antibiotic underdosing in critically ill patients have not been described in large-scale studies. The objective of this study was to describe pharmacokinetic/pharmacodynamic (PK/PD) target non-attainment envisioning empirical dosing in critically ill patients and considering a worst-case scenario as well as to identify patient characteristics that are associated with target non-attainment.
METHODS: This analysis uses data from the DALI study, a prospective, multi-centre pharmacokinetic point-prevalence study. For this analysis, we assumed that these were the concentrations that would be reached during empirical dosing, and calculated target attainment using a hypothetical target minimum inhibitory concentration (MIC), namely the susceptibility breakpoint of the least susceptible organism for which that antibiotic is commonly used. PK/PD targets were free drug concentration maintained above the MIC of the suspected pathogen for at least 50 % and 100 % of the dosing interval respectively (50 % and 100 % f T (>MIC)). Multivariable analysis was performed to identify factors associated with inadequate antibiotic exposure.
RESULTS: A total of 343 critically ill patients receiving eight different β-lactam antibiotics were included. The median (interquartile range) age was 60 (47-73) years, APACHE II score was 18 (13-24). In the hypothetical situation of empirical dosing, antibiotic concentrations remained below the MIC during 50 % and 100 % of the dosing interval in 66 (19.2 %) and 142 (41.4 %) patients respectively. The use of intermittent infusion was significantly associated with increased risk of non-attainment for both targets; creatinine clearance was independently associated with not reaching the 100 % f T( >MIC) target.
CONCLUSIONS: This study found that-in empirical dosing and considering a worst--case scenario--19 % and 41 % of the patients would not achieve antibiotic concentrations above the MIC during 50 % and 100 % of the dosing interval. The use of intermittent infusion (compared to extended and continuous infusion) was the main determinant of non-attainment for both targets; increasing creatinine clearance was also associated with not attaining concentrations above the MIC for the whole dosing interval. In the light of this study from 68 ICUs across ten countries, we believe current empiric dosing recommendations for ICU patients are inadequate to effectively cover a broad range of susceptible organisms and need to be reconsidered.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25053248     DOI: 10.1007/s00134-014-3403-8

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  39 in total

1.  Can PK/PD be used in everyday clinical practice.

Authors:  Francesco Scaglione
Journal:  Int J Antimicrob Agents       Date:  2002-04       Impact factor: 5.283

2.  Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics.

Authors:  Marta Ulldemolins; Jason A Roberts; Steven C Wallis; Jordi Rello; Jeffrey Lipman
Journal:  J Antimicrob Chemother       Date:  2010-06-08       Impact factor: 5.790

3.  Do we understand the impact of altered physiology, consequent interventions and resultant clinical scenarios in the intensive care unit? The antibiotic story.

Authors:  J Lipman; A A Udy; J A Roberts
Journal:  Anaesth Intensive Care       Date:  2011-11       Impact factor: 1.669

4.  Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients.

Authors:  Mieke Carlier; Michaël Noë; Jan J De Waele; Veronique Stove; Alain G Verstraete; Jeffrey Lipman; Jason A Roberts
Journal:  J Antimicrob Chemother       Date:  2013-06-25       Impact factor: 5.790

5.  Augmented creatinine clearance in traumatic brain injury.

Authors:  Andrew Udy; Robert Boots; Siva Senthuran; Janine Stuart; Renae Deans; Melissa Lassig-Smith; Jeffrey Lipman
Journal:  Anesth Analg       Date:  2010-11-03       Impact factor: 5.108

6.  Optimization of meropenem dosage in the critically ill population based on renal function.

Authors:  Jared L Crandon; Robert E Ariano; Sheryl A Zelenitsky; Anthony M Nicasio; Joseph L Kuti; David P Nicolau
Journal:  Intensive Care Med       Date:  2010-12-07       Impact factor: 17.440

7.  Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Pierre-François Laterre; Thierry Dugernier; Herbert Spapen; Isabelle Delattre; Xavier Wittebole; Daniel De Backer; Brice Layeux; Pierre Wallemacq; Jean-Louis Vincent; Frédérique Jacobs
Journal:  Crit Care       Date:  2010-07-01       Impact factor: 9.097

8.  Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia.

Authors:  Anouk E Muller; Nieko Punt; Johan W Mouton
Journal:  J Antimicrob Chemother       Date:  2012-11-28       Impact factor: 5.790

9.  DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic.

Authors:  Jason A Roberts; Jan J De Waele; George Dimopoulos; Despoina Koulenti; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; Jeffrey Lipman
Journal:  BMC Infect Dis       Date:  2012-07-06       Impact factor: 3.090

10.  DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?

Authors:  Jason A Roberts; Sanjoy K Paul; Murat Akova; Matteo Bassetti; Jan J De Waele; George Dimopoulos; Kirsi-Maija Kaukonen; Despoina Koulenti; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; Jeffrey Lipman
Journal:  Clin Infect Dis       Date:  2014-01-14       Impact factor: 9.079

View more
  52 in total

Review 1.  [Antibiotic stewardship : Measures for optimizing prescription of anti-infective agents].

Authors:  C Lanckohr; H Bracht
Journal:  Anaesthesist       Date:  2018-01       Impact factor: 1.041

Review 2.  Challenges in the management of septic shock: a narrative review.

Authors:  Daniel De Backer; Maurizio Cecconi; Jeffrey Lipman; Flavia Machado; Sheila Nainan Myatra; Marlies Ostermann; Anders Perner; Jean-Louis Teboul; Jean-Louis Vincent; Keith R Walley
Journal:  Intensive Care Med       Date:  2019-02-11       Impact factor: 17.440

3.  The research agenda in VAP/HAP: next steps.

Authors:  Michael S Niederman; Ignacio Martin-Loeches; Antoni Torres
Journal:  Intensive Care Med       Date:  2017-02-14       Impact factor: 17.440

Review 4.  What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.

Authors:  Karen Bush; Malcolm G P Page
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-04       Impact factor: 2.745

5.  Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearance.

Authors:  Stephen Y Liang; Anand Kumar
Journal:  Curr Infect Dis Rep       Date:  2015-07       Impact factor: 3.725

6.  Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.

Authors:  Mohd H Abdul-Aziz; Helmi Sulaiman; Mohd-Basri Mat-Nor; Vineya Rai; Kang K Wong; Mohd S Hasan; Azrin N Abd Rahman; Janattul A Jamal; Steven C Wallis; Jeffrey Lipman; Christine E Staatz; Jason A Roberts
Journal:  Intensive Care Med       Date:  2016-01-11       Impact factor: 17.440

7.  Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit.

Authors:  Mohd H Abdul-Aziz; Azrin N Abd Rahman; Mohd-Basri Mat-Nor; Helmi Sulaiman; Steven C Wallis; Jeffrey Lipman; Jason A Roberts; Christine E Staatz
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

8.  Antibiotic dosing in the critically ill: asking the same questions but expecting different answers.

Authors:  P Póvoa; I Spriet; J R Zahar
Journal:  Intensive Care Med       Date:  2014-09-23       Impact factor: 17.440

9.  Focus on antimicrobial use in the era of increasing antimicrobial resistance in ICU.

Authors:  Matteo Bassetti; Garyphallia Poulakou; Jean-François Timsit
Journal:  Intensive Care Med       Date:  2016-04-04       Impact factor: 17.440

10.  Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients.

Authors:  Joan Antoni Schoenenberger-Arnaiz; Faten Ahmad-Diaz; Mar Miralbes-Torner; Ana Aragones-Eroles; Manuel Cano-Marron; Mercedes Palomar-Martinez
Journal:  Eur J Hosp Pharm       Date:  2019-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.